Revenue and Overseas Sales Targets for the Fiscal Year Ending March 2022
First written in FY2020-Q2. 1 of 6 entries say "Restated". Latest entry: FY2022.
1 other company's latest entry also says "Achieved".
- FY2022AchievedAnnual report
「Although the period covered by this medium-term management plan was affected by the unforeseen spread of COVID-19, resulting in stagnation in domestic and overseas markets and delays in research and development activities, as described above, we achieved a certain level of progress on the 3 priority measures and met all the numerical targets announced when the plan was formulated.」
For the fiscal year ended March 2022, net sales were ¥34.8 billion, ordinary profit was ¥5.39 billion, SKK EBITDA was ¥5.54 billion, and the overseas sales ratio was 56.6%, meaning that all targets set when the plan was formulated were achieved. - FY2022-Q3Reported nine-month results for the final yearAnnual report
「Revenue for the cumulative third quarter of the current consolidated fiscal year, from 1 April 2021 to 31 December 2021, was ¥28.145 billion, up 37.0% from the same period of the previous year. This reflected the impact of domestic drug price reductions, a rebound from the impact of the spread of COVID-19 in Japan and overseas in the same period of the previous year, a substantial increase in royalties, which were reclassified from non-operating income to revenue from the fiscal year ending March 2022, and solid growth in overseas products. Operating profit increased 283.7% to ¥6.234 billion. Although SG&A expenses, including R&D expenses, increased mainly as additional clinical trials progressed for SI-6603, a treatment for lumbar disc herniation, being conducted in the United States, the effect of higher revenue more than offset the increase. Ordinary profit increased 231.5% to ¥6.905 billion.」
For the final year of the fiscal year ending March 2022, the company reported cumulative nine-month revenue of ¥28.145 billion, operating profit of ¥6.234 billion and ordinary profit of ¥6.905 billion. The results tracking progress against the existing numerical targets were updated. - FY2022-Q2Reported first-half results for the final yearAnnual report
「Revenue for the cumulative second quarter of the current consolidated fiscal year, from 1 April 2021 to 30 September 2021, was ¥20.530 billion, up 54.6% from the same period of the previous year. This reflected the impact of domestic drug price reductions, a rebound from the impact of the spread of COVID-19 in Japan and overseas in the same period of the previous year, a substantial increase in royalties, which were reclassified from non-operating income to revenue from the current period, and the launch of Joycle, a joint-function improvement agent.」
Although the company stated that there had been no material change to the numerical targets for the fiscal year ending March 2022, it reported first-half results for the final year including revenue of ¥20.530 billion and ordinary profit of ¥6.393 billion. - FY2021Reported second-year resultsAnnual report
「Revenue for the period was ¥27.662 billion, down 3.4% year on year, due to the impact of drug price reductions, as well as a decline in outpatient visits accompanying the spread of COVID-19.」
Against the targets for the fiscal year ending March 2022, revenue for the fiscal year ended March 2021 was ¥27.662 billion, ordinary profit was ¥3.024 billion and the overseas sales ratio was 49.6%. The targets themselves remain unchanged. - FY2020-Q3RestatedAnnual report
「The numerical targets for the fiscal year ending March 2022, the final year of the medium-term management plan covering the fiscal years ending March 2020 through March 2022, are as follows: revenue, ¥28.3 billion; ordinary profit, ¥4.5 billion; SKK EBITDA, ¥5.0 billion; overseas sales ratio, 50.0%.」
The company continues to target revenue of ¥28.3 billion, ordinary profit of ¥4.5 billion, SKK EBITDA of ¥5.0 billion and an overseas sales ratio of 50.0% for the fiscal year ending March 2022. - FY2020-Q2First statedAnnual report
「The numerical targets for the fiscal year ending March 2022, the final year of the medium-term management plan covering the fiscal years ending March 2020 through March 2022, are as follows: revenue, ¥28.3 billion; ordinary profit, ¥4.5 billion; SKK EBITDA, ¥5.0 billion; overseas sales ratio, 50.0%.」
For the fiscal year ending March 2022, the company identified targets of revenue of ¥28.3 billion, ordinary profit of ¥4.5 billion, SKK EBITDA of ¥5.0 billion and an overseas sales ratio of 50.0%. Revenue was the same as the actual result for the fiscal year ended March 2019, while the company aimed to increase ordinary profit, SKK EBITDA and the overseas sales ratio.